DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Radiation: post-mastectomy radiation therapy (PMRT)
Device: tissue expander (TE)
Device: acellular dermal matrix (ADM)

First Posted Date: 2012-08-14

Last Posted Date: 2019-08-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT01664091

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Not Applicable

Withdrawn

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ferumoxytol

First Posted Date: 2012-08-13

Last Posted Date: 2020-10-19

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01663090

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

and more 1 locations

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Bendamustine
Drug: Cytarabine

First Posted Date: 2012-08-10

Last Posted Date: 2024-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01661881

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Phase 2

Withdrawn

Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Olaparib

First Posted Date: 2012-08-10

Last Posted Date: 2012-08-21

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01661868

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pilot Study for Young Women's Intervention

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: YWI
Behavioral: Physical Activity

First Posted Date: 2012-07-23

Last Posted Date: 2013-01-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 93

Registration Number: NCT01647594

Locations: 🇺🇸
Texas Oncology Cancer Center, Houston, Texas, United States
🇺🇸
Eastern Maine Medical Center, Brewer, Maine, United States
🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States

and more 1 locations

Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Young Women's Intervention (YWI)
Behavioral: Physical Activity Intervention (PAI)

First Posted Date: 2012-07-23

Last Posted Date: 2020-07-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 467

Registration Number: NCT01647607

Locations: 🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Presence Resurrection Medical Center, Chicago, Illinois, United States

and more 1 locations

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1

Completed

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: BYL719 and Olaparib
Drug: BKM120 and Olaparib

First Posted Date: 2012-06-20

Last Posted Date: 2021-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 118

Registration Number: NCT01623349

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: PCI-32765

First Posted Date: 2012-06-08

Last Posted Date: 2020-01-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT01614821

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Phase 1

Withdrawn

Conditions: Pancreatic Cancer, Metastatic

Interventions: Drug: Gemcitabine, Erlotinib, OSI-906
Drug: Gemcitabine, Erlotinib

First Posted Date: 2012-05-17

Last Posted Date: 2013-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01600807

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma

Phase 1

Withdrawn

Conditions: Squamous Cell Carcinoma of the Oropharynx

Interventions: Radiation: Stereotactic Body Radiotherapy

First Posted Date: 2012-04-26

Last Posted Date: 2015-09-04

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01586182

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy